Illumina Inc., a leading biotechnology company, has agreed to pay $9.8 million to settle allegations that it sold genomic sequencing systems with serious cybersecurity flaws to U.S. federal ...

Illumina CEO Jacob Thaysen made clear the sequencing giant is returning to its traditional role of creating instruments for researchers.

Illumina and Regeneron are taking stakes in health data company Truveta to help fund research that may dwarf previous DNA sequencing projects.

BIOS/UEFI vulnerabilities in the iSeq 100 DNA sequencer from U.S. biotechnology company Illumina could let attackers disable devices used for detecting illnesses and developing vaccines.

China banned the import of Illumina Inc. gene-sequencing machines as part of a wave of retaliatory measures against fresh US tariffs on all Chinese goods, deepening the US company’s woes in one ...

Illumina is suing Element Biosciences, with the sequencing giant accusing its smaller rival of infringing on five of its patents covering flow cell and imaging technologies used in automated ...